MarketPulse
E

$ESPR

10 articles found
6 positive
4 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Halper Sadeh Llc

Major Law Firm Probes Four Corporate Deals Over Shareholder Value Concerns

Halper Sadeh LLC investigates potential undervalued acquisitions at $SILA, $ESPR, $CRBG, and $EQH, alleging fiduciary duty breaches and inadequate shareholder consideration.
EQHEQHpAEQHpCESPRCRBD+2securities fraudshareholder rights
GlobeNewswire Inc.GlobeNewswire Inc.··Brodsky & Smith

Law Firm Probes Four M&A Deals Over Fiduciary Duty Concerns

Brodsky & Smith investigates four merger transactions, questioning whether boards ensured fair shareholder value in acquisitions valued at $3.16 to $35.00 per share.
ESPRSKYTLSTASILAshareholder rightsacquisition
BenzingaBenzinga··Vandana Singh

Esperion Therapeutics Surges on $1.1B Archimed Acquisition Deal

Esperion Therapeutics shares surge following $1.1B Archimed acquisition announcement at $3.16 per share plus contingent value rights.
ESPRacquisitioncontingent value rights
GlobeNewswire Inc.GlobeNewswire Inc.··Juan Monteverde, Monteverde & Associates Pc

Class Action Probe Launched Into Esperion's $3.16 ARCHIMED Deal

Class action firm investigates Esperion Therapeutics' $3.16-per-share ARCHIMED sale, questioning deal fairness to shareholders.
ESPRacquisitionclass action
BenzingaBenzinga··Nabaparna Bhattacharya

Esperion Soars 57% on $1.1B ARCHIMED Buyout Deal

Esperion Therapeutics agreed to be acquired by ARCHIMED for $1.1 billion, with shareholders receiving $3.16 per share plus up to $100 million in contingent payments—a 58% premium driving 57.5% premarket gains.
ESPRacquisitionshareholder value
BenzingaBenzinga··Na

Athyrium Backs Esperion's $50M Japan Deal to Fund Corstasis Acquisition

Athyrium invests $50M in Esperion via Japan royalty financing to fund Corstasis acquisition, bringing first FDA-approved intranasal loop diuretic to portfolio.
ESPRM&AJapan market
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Esperion Closes Corstasis Deal, Adding First Nasal Loop Diuretic to Heart Drug Arsenal

Esperion completes acquisition of Corstasis, adding Enbumyst, first FDA-approved nasal spray loop diuretic, to expand its cardiovascular product portfolio.
ESPRacquisitionFDA approval
BenzingaBenzinga··Na

Esperion Closes Corstasis Acquisition, Adds First Nasal Spray Loop Diuretic to CV Portfolio

Esperion closes Corstasis acquisition, gaining FDA-approved Enbumyst nasal spray loop diuretic for heart failure treatment, leveraging existing cardiovascular commercial infrastructure.
ESPRacquisitionFDA approval
BenzingaBenzinga··Nabaparna Bhattacharya

Esperion Acquires Enbumyst Maker Corstasis for $75M in Cash-Plus-Milestone Deal

Esperion acquires Corstasis for $75M upfront plus $180M in milestones, gaining FDA-approved nasal spray diuretic Enbumyst for heart failure treatment.
ESPRacquisitionFDA-approved
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Esperion Secures Fifth Settlement with Generic Drug Maker Over NEXLETOL, NEXLIZET Patents

Esperion secures fifth settlement with generic drugmaker Alkem, extending market exclusivity for cholesterol drugs NEXLETOL and NEXLIZET through April 2040.
SDZNYESPRpatent settlementgeneric drugs